Top 50 Biotech Investors

A list of 50 investors investing in biotech. Updated every month. Powered by Shizune.
Investors in the list rank based on the number of investments in Biotech companies. The investor list contains both angel investors and VC funds. You can find favourite industries and stages of each investor on the list.
Biotech Investors
Name Number of investments Relevant deals Favorite stages Favorite industries Description In
ARCH Venture Partners 254 87 Series A; Series B; Series C Science/Engineering; Biotechnology; Health Care ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
OrbiMed 341 77 Series B; Series A; Series C Health Care; Science/Engineering; Biotechnology Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Alexandria Venture Investments 160 72 Series A; Series B; Series C Science/Engineering; Biotechnology; Health Care Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Sofinnova Partners 193 70 Series A; Series B; Series C Science/Engineering; Biotechnology; Health Care Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
New Enterprise Associates 1114 65 Series B; Series A; Series C Software; Science/Engineering; Health Care New Enterprise Associates, Inc. is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors, and geographies. With over $19 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’slifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 210 portfolio company IPOs and more than 360 acquisitions.
Novo Holdings 186 61 Series A; Series B; Series C Health Care; Science/Engineering; Biotechnology Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Versant Ventures 210 61 Series A; Series B; Series C Health Care; Science/Engineering; Biotechnology Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Atlas Venture 295 58 Series A; Series B; Seed Science/Engineering; Health Care; Biotechnology Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value.
F-Prime Capital 243 57 Series A; Series B; Series C Health Care; Science/Engineering; Biotechnology We create and invest in healthcare and technology companies that improve lives all over the world.
5AM Ventures 135 56 Series A; Series B; Series C Science/Engineering; Biotechnology; Health Care 5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
MPM Capital 174 55 Series A; Series B; Series C Health Care; Science/Engineering; Biotechnology Powering Breakthroughs in Life Sciences
Third Rock Ventures 116 53 Series A; Series B; Series C Health Care; Biotechnology; Science/Engineering Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.
Novartis Venture Fund 169 52 Series B; Series A; Series C Health Care; Science/Engineering; Biotechnology Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capitalefficiency in the program.We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100'000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates. SectorsNew therapeutics & platformsMedical devices/implantsDiagnostics/biomarkersDrug delivery/biopolymersGeographyUSA/CanadaEuropeSwitzerlandAsia/Pacific
Khosla Ventures 629 51 Series A; Series B; Seed Software; Science/Engineering; Health Care Khosla Ventures is a venture capital firm started in 2004 by Vinod Khosla, Co-Founder of Sun Microsystems. The firm provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies.With over $15b assets under management, the firm focuses on a range of areas including consumer, enterprise, education,advertising, financial services, semiconductors, health, big data, agriculture, food, sustainable energy, and robotics. Khosla Ventures is headquartered in Menlo Park, California.
Polaris Partners 321 49 Series B; Series A; Series C Health Care; Science/Engineering; Biotechnology Polaris Partners ​has over 20-year history partnering with ​repeat entrepreneurs and innovators who are improving the way people live and work. The ​multibillion-dollar firm invests in healthcare and technology companies ​across all stages, from founding to profitable growth. ​Polaris has offices in Boston and San Francisco. ​Polaris Partners wasfounded in 1996 and is headquartered in Boston, Massachusetts.
BioAdvance 109 47 Seed; Funding Round; Series A Health Care; Science/Engineering; Biotechnology BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.
RA Capital Management 218 45 Series B; Series A; Series C Science/Engineering; Health Care; Biotechnology RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. Their team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and board levels. Theyinvest in companies with promising technologies and products. Their approach is to achieve a superior understanding of data, experimental/trial design, regulatory process, and commercial potential. When appropriate, they can offer their portfolio companies leads on in-licensing opportunities and strategic partnerships, as well as insight into the demands of the public markets.
UK Innovation & Science Seed Fund 80 44 Seed; Funding Round; Series A Science/Engineering; Health Care; Biotechnology UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
SR One 135 43 Series A; Series B; Series C Health Care; Biotechnology; Science/Engineering SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
M Ventures 95 43 Series A; Series B; Seed Science/Engineering; Health Care; Biotechnology Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Boehringer Ingelheim Venture Fund 74 42 Series A; Series B; Seed Science/Engineering; Biotechnology; Health Care The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.
Life Sciences Partners 122 42 Series A; Series B; Series C Health Care; Science/Engineering; Biotechnology LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing to private and public life-science companies. Since the late 1980s, LSP's management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. For example,LSP was a founding investor in Crucell, DNage, Qiagen, Rhein Biotech and Pharming. With over EUR 500 million under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe's largest and most experienced specialist life-science investors.
Fifty Years 120 41 Seed; Series A; Series B Science/Engineering; Health Care; Biotechnology WE BACK HEROES using technology to solve the world's biggest problems
Takeda Ventures 84 41 Series A; Series B; Funding Round Health Care; Biotechnology; Science/Engineering Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. We are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. We also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Our goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Pfizer Venture Investments 115 40 Series B; Series A; Series C Health Care; Biotechnology; Science/Engineering Pfizer Venture Investments is a venture capital firm.
Frazier Healthcare Partners 149 39 Series A; Series B; Post-IPO Equity Health Care; Science/Engineering; Biotechnology Frazier Healthcare Partners: Investing exclusively in healthcare for 25 years.
Casdin Capital 157 39 Series B; Series A; Series C Science/Engineering; Biotechnology; Health Care Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.
Canaan Partners 426 38 Series A; Series B; Series C Software; Science/Engineering; Health Care Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Seventure Partners 160 38 Series A; Series B; Funding Round Science/Engineering; Health Care; Biotechnology Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.
Hatteras Venture Partners 100 38 Series A; Series B; Funding Round Health Care; Science/Engineering; Biotechnology Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Amgen Ventures 104 37 Series B; Series A; Series C Biotechnology; Science/Engineering; Health Care Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, andcardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.
Connecticut Innovations 184 37 Series A; Seed; Funding Round Health Care; Science/Engineering; Software At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Parkwalk Advisors 174 37 Seed; Series A; Series B Science/Engineering; Health Care; Software Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Life Science Angels 77 36 Funding Round; Seed; Series A Health Care; Science/Engineering; Biotechnology Life Science Angels, Inc. (LSA) is the premier angel investment group focused solely on healthcare investing, including medical devices, diagnostics, pharmaceuticals, biotechnology, and digital health.
The Column Group 100 36 Series A; Series B; Series C Biotechnology; Science/Engineering; Health Care The Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies
Northpond Ventures 95 36 Series A; Series B; Series C Science/Engineering; Biotechnology; Health Care Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Lux Capital 282 36 Series A; Seed; Series B Software; Science/Engineering; Health Care Lux Capital Management manages of $4 billion in assets focused on founding, seed, early-stage, and growth investments in the physical, material and life sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures our portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
DCVC 265 36 Seed; Series A; Series B Software; Science/Engineering; Data and Analytics Deep Tech VC firm with over $3B under management
Bpifrance 480 35 Funding Round; Seed; Series A Software; Science/Engineering; Health Care Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.Bpifrance was founded in 2012 and is based in Maisons-alfort, Ile-de-France,France.
Broadview Ventures 63 34 Series A; Seed; Debt Financing Health Care; Science/Engineering; Biotechnology Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures.The FoundationLeducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support.With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.
Pontifax 91 34 Series A; Series B; Series C Health Care; Science/Engineering; Biotechnology Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.
HealthCap 103 34 Series B; Series A; Funding Round Health Care; Biotechnology; Science/Engineering HealthCap is a family of multi stage venture capital funds, investing globally in life sciences, with the Odlander Fredrikson Group as their exclusive investments advisor. With committed capital exceeding € 800 million, HealthCap is one of the largest specialized provider of venture capital within life sciences Europe.
Oxford Technology Management 103 34 Seed; Funding Round; Series A Science/Engineering; Health Care; Biotechnology Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.
Lilly Asia Ventures 132 33 Series B; Series A; Series C Health Care; Science/Engineering; Biotechnology Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Roche Venture Fund 103 33 Series B; Series A; Series C Health Care; Biotechnology; Science/Engineering The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.
High-Tech Grunderfonds 270 33 Seed; Series A; Funding Round Software; Science/Engineering; Health Care High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 895.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 500 startups since 2005. Driven by their expertise, entrepreneurial spirit, and passion, its teamof experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry, and life sciences.To date, external investors have injected over EUR 2 billion into the HTGF portfolio via about 1,400 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Banking Group, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.
Omega Funds 107 32 Series B; Series A; Series C Science/Engineering; Health Care; Biotechnology We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Sofinnova Investments 161 32 Series B; Series C; Series A Health Care; Science/Engineering; Biotechnology Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.
KdT Ventures 52 31 Seed; Series A; Series B Science/Engineering; Health Care; Biotechnology KdT Ventures is the standard for early-stage frontier science investing.
BioMedPartners 79 31 Series A; Series B; Series C Health Care; Biotechnology; Science/Engineering BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Powered by Shizune.co An algorithm that finds investors. Trusted by 3,000+ startups.